Cytovance® Biologics, Inc. announces completion of first batch in new state-of-the-art 1000L microbial facility

OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) — Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces completion of first batch in new state-of-the-art 1000L microbial facility.  
“The Cytovance team has successfully completed our first run in our new state-of-the-art microbial facility,” said Michael O Mara, SVP of Manufacturing. "It was a great moment for the late phase client and the entire Cytovance team.” The 30,000-square foot facility houses a 14L fermentor, a 300L SUF (Q3 2018) and a 1000L working volume Dakota Fermentor.  Also, housed in this facility is a GEA Homogenizer, Alfa Laval MBPX810 Disc Stack Centrifuge and a P-12 Powerfuge. The purification suite features 2 x 5000L imPULSE Mixers for refolding, Chromatography skid, a Millipore TFF Skid, 1” & 10mm AKTA Process and AKTA Ready, all with gradient function.
“The upstream material is processed by the downstream purification equipment,” said Stephanie Wickham, Director of Manufacturing Sciences.  “Our 2x5000L imPULSE Mixers give us exactly what we need for our refold processes.  Highly efficient mixing with very low shear rates, is critical in the protein refolding process and with a large turndown ratio, we have the ability to process at a variety of refold volumes.”
By reallocating resources, hiring external contractors and improving efficiencies gained in equipment commissioned, Cytovance was able to have building 3500 up and running 4 months prior to the “go live” date.  This was a huge success not only for Cytovance but our client as well who needed the data gained for an FDA inspection.

Media Contact
Cheryl Tuck


Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.